Literature DB >> 18652319

[Effect of moxibustion on quality of life in hemodialysis patients].

Hui Sun1, Mo-Yan Qiu, Bao-Qing Li, Shao-Hua Wang, Zhong-Ying Chen, Yue Jiang, Jie Luan.   

Abstract

OBJECTIVE: To probe the effect of moxihustion on the quality of life in the end-stage renal failure patients in hemodialysis.
METHODS: Seventy-one hemodialysis patients were randomly divided into 2 groups, and the quality of life of all the patients was evaluated with the Kidney Disease Quality of Life Short Form (KDQOL-SF). The Control group were treated with routine comprehensive therapy (including hemodialysis and medication), and the observation group with the routine comprehensive therapy and moxibustion at Zusanli (ST 36), Guanyuan (CV 4), Sanyinjiao (SP 6). Changes of the quality of life in the patients before and after hemodialysis were recorded and analyzed.
RESULTS: After treatment there were significant differences between the two groups in DSF, RE and GH (P<0.05), and 7 fields including RE, BP, QSI and others significantly improved in the both groups (P<0.05). Additionally, the 4 fields including RP, EB, VT and WS significantly improved in the observation group (P<0.05).
CONCLUSION: Moxibustion can improve physical strength and mood in the quality of life of the hemodialysis patients; to evaluate the quality of life of hemodialysis patients should consider effects of society, climate and geographical condition and other factors.

Entities:  

Mesh:

Year:  2008        PMID: 18652319

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  2 in total

1.  Study protocol for a single-blind, placebo-controlled randomised trial of Tianjiu effects in patients with intradialytic hypotension.

Authors:  Ming-Yen Tsai; Yu-Jen Su; Hwee-Yeong Ng; Shih-Yu Chen; Yu-Chuen Huang; Chien-Hsing Wu; Yung-Hsiang Chen
Journal:  BMJ Open       Date:  2016-03-10       Impact factor: 2.692

2.  The effectiveness of moxibustion: an overview during 10 years.

Authors:  Song-Yi Kim; Younbyoung Chae; Seung Min Lee; Hyejung Lee; Hi-Joon Park
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-23       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.